linjc16/ctgov huggingface dataset:
Pilot Study on the Tolerability of Dietary Dried Plum

Study Overview
=================
Brief Summary
-----------------
Dried plums (Prunus domestica L.) have traditionally been recognized for their health benefits related to conditions such as constipation, irregular menstrual cycles and mouth sores. This dried fruit provides high levels of fiber, vitamins and minerals. Dried plum has also been shown in animal studies to have beneficial effects on bone and can prevent the loss of bone caused by low hormone levels such as occurs after surgical removal of the ovaries. We also have shown that dried plum can prevent the loss of bone associated with aging in mice. Very few therapies for osteoporosis actually reverse bone loss and improve bone strength. The potential therapeutic value of dried plum in men and women with hormone deficiency or age-related osteoporosis is clear.

Official Title
-----------------
Pilot Study on the Tolerability of Dietary Dried Plum

Conditions
-----------------
Healthy, Elderly

Intervention / Treatment
-----------------
* Dietary Supplement: dried plum powder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 50 yrs and 75 yrs Nonsmokers Normal renal and hepatic function Exclusion Criteria: Subjects who must follow a specific diet Subjects on any daily medications that affect bone health Subjects too heavy for the DEXA machine (weight limit 300 lbs) Subjects whose BMD by DEXA indicates osteoporosis Subjects unwilling to follow the diet specified Pregnant women Subjects who are unable to understand the consent form.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: dried plum<br>subjects will have 25% by weight (  600 kcal if eat 2500 kcal diet) of their usual diet substituted by dried plum powder | Dietary Supplement: dried plum powder<br>* subjects will have 25% of their diet substituted by dried plum powder<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| urinary calcium excretion |  | one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ability to tolerate the diet |  | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
healthy older people
Does the Recall by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?

Study Overview
=================
Brief Summary
-----------------
The propose of this study is to assess the effect of general practitioner's involvement in the stimulus invitation letter in colorectal cancer screening compared to sending the patient home test (stimulus 2 of reference as contained in the specifications).

Official Title
-----------------
Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening? A Cluster Randomised Controlled Study.

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Other: Co-signed Letter
* Other: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age : 50 to 74 years. Not having answered the first two solicitations of ADECA75 to participate in screening for colorectal cancer Exclusion Criteria: Patients who have a Fecal Occult Blood Test for less than 2 years or a colonoscopy within the past 5 years or excluded for medical reasons (according to information known from ADECA).

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>Patients receive by mail the materials needed for stool samples. | Other: Control<br>* No intervention (Patients receive by mail the materials needed for stool samples).<br>|
| Experimental: Co-signed Letter<br> | Other: Co-signed Letter<br>* Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Completion of Fecal Occult Blod Test | Increased number of patients who completed the test for faecal occult blood following the first solicitation with the letter co-signed by general practitioner, compared with the conventional solicition(including replies exclusions). | 7 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Delays from receipt of the letter and the completion of the test. |  | 7 months | 
| Proportion of uninterpretable test. |  | 7 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colorectal Cancer, Screening, General Practitioner, Fecal Occult Blood Tests
An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Study Overview
=================
Brief Summary
-----------------
Study GIPF-004 is an open-label, multicenter study that will enroll approximately 250 patients who complete Protocol GIPF-001. The purpose of this study is to assess the safety and efficacy of continued IFN-gamma 1b therapy in this well-defined cohort of patients for up to 48 weeks.

Official Title
-----------------
An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis.

Conditions
-----------------
Lung Disease, Pulmonary Fibrosis

Intervention / Treatment
-----------------
* Drug: interferon-gamma 1b


Participation Criteria
=================
Eligibility Criteria
-----------------
Male or Female Idiopathic Pulmonary Fibrosis 20-79 years Must have participated in the InterMune protocol GIPF-001 study.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: interferon-gamma 1b|200 mcg, SQ, 3x per week|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FVC, dyspnea, DLCO, A-a gradient at rest,SGRQ,survival time, use of supplemental oxygen, QOL SF-36, TLC, time to lung transplantation or death due to IPF |  | 48 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
idiopathic pulmonary fibrosis, IPF
Database of All Patients Who Have Undergone Pulmonary Function Testing at Singapore General Hospital

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to create a prospective database of all patients who have undergone pulmonary function testing from which the investigators can study the clinical phenotypes of various respiratory conditions. The investigators hope by understanding the differences in these myriad phenotypes to be able to provide individualized, patient-targeted therapy in the future.

Detailed Description
-----------------
Recent studies have shown that clinical phenotyping of patients with various respiratory conditions is important in the understanding of the disease process, clinical response to treatment, and prognosis. Pulmonary function testing is a very important aspect of clinical phenotyping in many respiratory conditions. Creating a database will enable us to study the various phenotypes within each respiratory condition. This will allow us to better understand each disease, with a view to provide personalized patient care targeted at their specific phenotype and hence better clinical outcomes.

Official Title
-----------------
Prospective Database of All Patients Who Have Undergone Pulmonary Function Testing at Singapore General Hospital

Conditions
-----------------
Obstructive Pulmonary Diseases, Restrictive Lung Disease, Cough, Dyspnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) All patients who have undergone pulmonary function testing at the Singapore General Hospital pulmonary function laboratory

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnoses based on pulmonary function test interpretation | Interpretation of pulmonary function tests by a certified respiratory physician | 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obstructive lung disease, restrictive lung disease, cough, dyspnea
Evaluation of a Cohort of Patients With Ehlers-Danlos Syndrome Treated With Orthopedic Surgery (SED-eval)

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess the joint involvement (shoulder - ankle - knee - elbow - wrist) in patients with Ehlers-Danlos Syndrome and treated by surgery.

Official Title
-----------------
Evaluation of a Cohort of Patients With Ehlers-Danlos Syndrome Treated With Orthopedic Surgery (SED-eval)

Conditions
-----------------
Ehlers-Danlos Syndrome

Intervention / Treatment
-----------------
* Behavioral: A joint functional score based on the affected joint


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient over 18 years-old suffering from Ehlers-Danlos Syndrome and belonging to the EDS cohort of Raymond Poincaré Hospital in Garches Patient with joint involvement of the shoulder treated by surgery Patient with ankle joint damage treated by surgery Patient with joint damage to the knee treated by surgery Patient with elbow joint damage treated by surgery Patient with joint involvement of the wrist treated by surgery Patient affiliated or beneficiary of a social security scheme Patient who has been informed of the research and does not object to the use of his data. Exclusion Criteria: Patient objecting to the use of their data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Elher-Danlos syndrome patients treated with orthopedic surgery<br> | Behavioral: A joint functional score based on the affected joint<br>* A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: Shoulder (SSV; QuickDash), Knee (Lysholm tenger), Ankle (EFAS), Elbow and wrist (QuickDash) )<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Joint function score according to the affected joint | A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: Shoulder (SSV; QuickDash), | 1 day | 
| Joint function score according to the affected joint | A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: Knee (Lysholm tenger), | 1 day | 
| Joint function score according to the affected joint | A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: Ankle (EFAS), | 1 day | 
| Joint function score according to the affected joint | A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: -Elbow and wrist (QuickDash) ) | 1 day |
Quantification of Radiological Pulmonary Involvement in Acute Respiratory Failure

Study Overview
=================
Brief Summary
-----------------
Acute respiratory failure (ARF) is a common condition and a common reason for urgent medical consultation. Assessing the extent of respiratory impairment is important to improve the management of patients with ARF. When Acute respiratory failure is caused by pathology of the pulmonary parenchyma, quantification of pulmonary radiographic involvement may be a component of the initial assessment of severity. This radiographic quantification would only be usable in clinical routine if it can be automated and provide a real-time result. The objective of this work is to assess the feasibility of an automated technique for quantifying radiological lung damage in situations of known or potential ARF.

Official Title
-----------------
Automated Quantification of Radiological Pulmonary Involvement in Acute Respiratory Failure

Conditions
-----------------
SARS (Severe Acute Respiratory Syndrome)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years of age Presenting a situation at risk of acute respiratory failure Requiring thorax imaging when they were treated. Exclusion Criteria: Patients with anatomically incomplete thoracic imaging (e.g., technical acquisition error).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective study of the relationship between severe forms of ARF and the extent of lung involvement |  | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SARS, Severe Acute Respiratory Syndrome, Automated quantification, Lung volume, Thorax imaging
Evaluation of the Atlas Genetics io® CTNG System

Study Overview
=================
Brief Summary
-----------------
Atlas Genetics io® system results are compared with those obtained from comparator devices.

Detailed Description
-----------------
Results from the Atlas Genetics io® system are compared with a Composite Infection Status obtained from testing on three commonly used comparator devices. This is a prospective, single-arm, multi-centre investigation enrolling up to 12,000 adult participants over 14 years of age who are undergoing testing for the presence of CT/NG.

Official Title
-----------------
IO-CTNG: A Multi-Centre Evaluation of the Atlas Genetics io® CTNG System Used in Centralised and Point of Care Settings

Conditions
-----------------
Chlamydia Trachomatis, Gonorrhea

Intervention / Treatment
-----------------
* Device: Atlas Genetics io® system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Symptomatic and asymptomatic individuals ≥14 years of age Exclusion Criteria: Treatment with antibiotics known to be effective against Chlamydia trachomatis and/or Neisseria gonorrhoeae within the previous 4 weeks before inclusion in the study. Unable to self-obtain a vaginal swab or urine sample of at least 30 mL

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Atlas Genetics io® system|Specimen Collection|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic Accuracy compared to positive Composite Infected Status from comparator devices | The assessment of the diagnostic accuracy of the study device as compared to positive Composite Infected Status from comparator devices | Up to 7 days |
Diagnostic Accuracy of Multislice CT Angiography for Acute Chest Pain

Study Overview
=================
Brief Summary
-----------------
The ACUTE CT trial is designed to test whether the assessment of chest structures by high-resolution multislice computed tomography (CT) provides equivalent diagnostic accuracy for patient with acute chest pain or other potential cardiac symptoms as compared to a standard of care evaluation.

Detailed Description
-----------------
Adults at low to intermediate risk of acute coronary syndrome who present to the Emergency Department with symptoms suggestive of cardiac ischemia will undergo a blinded cardiac CT followed by a standard of care (SOC) strategy. Significant coronary artery disease on CT (coronary stenosis >50%) will be compared to an adjudicated diagnosis derived from clinical data and other diagnostic tests based on the SOC strategy. Costs for the SOC evaluation will be collected and compared to a CT-based evaluation. Patients will be followed for 3 years after enrollment to evaluate prognosis.

Official Title
-----------------
Diagnostic Accuracy of Multislice CT Angiography for Acute Chest Pain - Assessment of Chest Pain Utilizing a Triple Rule Out Evaluation With Computed Tomography (ACUTE CT) Trial

Conditions
-----------------
Chest Pain, Acute Coronary Syndrome, Pulmonary Embolism, Aortic Dissection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Low to intermediate risk of angina with a TIMI ACS Risk Score ≤ 4 chest pain or other symptoms suggestive of ACS within 24 hours male ≥30 years or female ≥45 years old at least one cardiac risk factor no obvious cause for symptoms. Exclusion Criteria: known CAD ST segment elevation, new left bundle branch block or dynamic ECG changes creatinine ≥1.8 g/dL pregnant or lactating female hemodynamic or respiratory instability ongoing bronchospasm known iodinated contrast allergy atrial fibrillation or irregular heart rate

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic accuracy of CT compared to standard of care evaluation |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cost savings of CT-based evaluation compared to the standard of care evaluation |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute coronary syndrome, Coronary artery disease, cardiac imaging, computed tomography
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age, inclusive

Conditions
-----------------
Refractory Epilepsy

Intervention / Treatment
-----------------
* Drug: RWJ-333369


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-70 years old, Diagnosis of epilepsy for at least 1 year, Presenting, on average, at least 3 partial onset seizures per month, Currently treated with a stable dose (i.e., for at least 4 weeks) of no more than 3 anti-epileptic drugs (AEDs), Exclusion Criteria: Have experienced status epilepticus in the past 3 months, Have any serious diseases, History of major psychiatric disorders within the past 2 years. Have received an experimental drug/device within the past 30 days Are pregnant or breastfeeding.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: RWJ-333369|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |